|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0033414,
umls-concept:C0086597,
umls-concept:C0205191,
umls-concept:C0332157,
umls-concept:C0334227,
umls-concept:C0431085,
umls-concept:C0796392,
umls-concept:C1527249,
umls-concept:C1622501,
umls-concept:C1704259,
umls-concept:C1705987
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2011-4-13
|
|
pubmed:abstractText |
Bevacizumab (Bev), a monoclonal antibody to vascular endothelial growth factor (VEGF), is used in combination with chemotherapy for the treatment of metastatic colorectal cancer (CRC). The effects of Bev on angiogenesis have been well described, but the direct effect of Bev on tumour cells is unknown. This study was carried out to determine the molecular and phenotypic changes in CRC cells after chronic Bev exposure in vitro.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
12
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1270-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21407219-Animals,
pubmed-meshheading:21407219-Antibodies, Monoclonal,
pubmed-meshheading:21407219-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21407219-Antineoplastic Agents,
pubmed-meshheading:21407219-Carcinoma,
pubmed-meshheading:21407219-Cell Line, Tumor,
pubmed-meshheading:21407219-Cell Movement,
pubmed-meshheading:21407219-Colorectal Neoplasms,
pubmed-meshheading:21407219-Drug Resistance, Neoplasm,
pubmed-meshheading:21407219-HCT116 Cells,
pubmed-meshheading:21407219-Humans,
pubmed-meshheading:21407219-Mice,
pubmed-meshheading:21407219-Mice, Nude,
pubmed-meshheading:21407219-Neoplasm Metastasis,
pubmed-meshheading:21407219-Signal Transduction,
pubmed-meshheading:21407219-Time Factors,
pubmed-meshheading:21407219-Transplantation, Heterologous
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.
|
|
pubmed:affiliation |
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Unit 173, PO Box 301402, Houston, TX 77030-1402, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies,
Research Support, N.I.H., Extramural
|
